

Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data



NEWS RELEASE BY POOLBEG PHARMA PLC

London, UK | March 02, 2023 05:59 AM Eastern Standard Time



Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious disease focused biopharma company's lead molecule.

Skillington says that he "couldn't be happier" with the results, that he says will help "ramp up the discussions" with potential partners.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Tags

HEALTH

PHARMA

BIOTECH

LUPUS

INFECTIOUS DISEASES